Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immuno-oncology
Biotech
BMS exits next-gen Yervoy pact, taking $300M in biobucks with it
Bristol Myers Squibb is walking away from CytomX's potential successor to Yervoy and wiping $300 million off the value of the alliance in the process.
Nick Paul Taylor
Mar 12, 2024 7:07am
Ultimovacs' cancer vaccine flunks another checkpoint combo test
Mar 7, 2024 6:14am
Astellas bets more than $800M on Kelonia's delivery tech
Feb 15, 2024 6:30pm
Eisai’s Cheung takes top spot at NextPoint Therapeutics
Feb 1, 2024 10:40am
Novartis axes TIM-3 cancer candidate after phase 3 flop
Jan 31, 2024 6:59am
Roche racks up phase 3 TIGIT win, but trial design leaves doubts
Jan 17, 2024 5:34am